share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

SEC announcement ·  Mar 13 05:49
Summary by Futu AI
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, engaged in multiple transactions involving the company's common stock between March 10, 2024, and March 12, 2024. Kasinger acquired a total of 7,750 shares through the exercise of derivative securities on March 10 and March 11. Subsequently, he sold 2,801 shares on March 11 at a price of $78.26 per share and 1,146 shares on March 12 at $74.44 per share, resulting in a total sale value of approximately $304,514.50. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics common stock amounted to 61,174 shares. The transactions are reported to be in progress.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, engaged in multiple transactions involving the company's common stock between March 10, 2024, and March 12, 2024. Kasinger acquired a total of 7,750 shares through the exercise of derivative securities on March 10 and March 11. Subsequently, he sold 2,801 shares on March 11 at a price of $78.26 per share and 1,146 shares on March 12 at $74.44 per share, resulting in a total sale value of approximately $304,514.50. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics common stock amounted to 61,174 shares. The transactions are reported to be in progress.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.